Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04379362 | MRI-guided Focal Laser Ablation(Unicorn) | unknown | Phase 2 | 53 | Radboud University Medical CenterOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT03305224 | The Combination Therapy With Ra-223 and Enzalutamide(CORE-OCU) | unknown | Phase 2 | 10 | Taro Iguchi, MD, PHDOTHER | 1 | Sep 9, 2021 | clinicaltrials |
| NCT03040791 | Nivolumab in Prostate Cancer With DNA Repair Defects (ImmunoProst Trial)(ImmunoProst) | unknown | Phase 2 | 38 | Hospital Moinhos de VentoOTHER | 1 | Aug 26, 2021 | clinicaltrials |
| NCT03050866 | Cabazitaxel in mCRPC Patients With AR-V7 Positive Circulating Tumor Cells (CTCs)(CABA-V7) | unknown | Phase 2 | 140 | Erasmus Medical CenterOTHER | 1 | Aug 20, 2021 | clinicaltrials |
| NCT04985110 | Administration of Antibiotic Prophylaxis for Transperineal Prostate Biopsy in Cipto Mangunkusumo Hospital | unknown | Phase 2 | 78 | Indonesia UniversityOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT04926155 | The Effect of Metformin in Patients With Metastatic Castration-resistant Prostate Cancer | unknown | Phase 2 | 234 | Sun Yat-sen UniversityOTHER | 1 | Jun 14, 2021 | clinicaltrials |
| NCT04839055 | The Effects of Coenzyme A Combined With Abiraterone on Patients With CRPC(CoA-CRPC) | unknown | Phase 1 / Phase 2 | 50 | Jiangnan UniversityOTHER | 1 | Apr 9, 2021 | clinicaltrials |
| NCT02944201 | Beta Adrenergic Receptor Blockade as a Novel Therapy for Patients With Adenocarcinoma of the Prostate | unknown | Phase 2 | 22 | Montefiore Medical CenterOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT04736108 | Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate | unknown | Phase 2 | 50 | West China HospitalOTHER | 1 | Feb 8, 2021 | clinicaltrials |
| NCT03432780 | Radiation-hormone and Docetaxel VS Radiation-hormone in Patients With High-Risk Localized Prostate Cancer(QRT-SOGUG) | unknown | Phase 2 | 134 | Spanish Oncology Genito-Urinary GroupOTHER | 0 | Jan 22, 2021 | clinicaltrials |
| NCT04622761 | Phase II Study of the Use of Neoadjuvant Cabazitaxel With Hormonal Treatment in Patients Operable Prostate Cancer, Assess the Efficacy and Toxicity of Cabazitaxel, and Explore Potential Predictive and Prognostic Markers of Clinical Outcome(CHROME) | unknown | Phase 2 | 120 | The Clatterbridge Cancer Centre NHS Foundation TrustOTHER | 0 | Jan 5, 2021 | clinicaltrials |
| NCT01835977 | Multi-Center Randomized Clinical Trial Irreversible Electroporation for the Ablation of Localized Prostate Cancer | unknown | Phase 2 | 106 | Clinical Research Office of the Endourological SocietyOTHER | 0 | Dec 16, 2020 | clinicaltrials |
| NCT01505075 | Safety and Efficacy Study of Hypofractionated Radiotherapy and Androgen Deprivation Therapy for Prostate Cancer(pHART8) | unknown | Phase 1 / Phase 2 | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT01953055 | SABR Including Regional Lymph Node Irradiation for Patients With High Risk Prostate Cancer (SATURN)(SATURN) | unknown | Phase 1 / Phase 2 | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT02031328 | Two StereoTactic Ablative Adaptive Radiotherapy Treatments for Localized Prostate Cancer(2STAR) | unknown | Phase 1 / Phase 2 | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT03307460 | uPAR-PET/MRI in Patients With Prostate Cancer for Evaluation of Tumor Aggressiveness | unknown | Phase 2 | 52 | Rigshospitalet, DenmarkOTHER | 1 | Nov 23, 2020 | clinicaltrials |
| NCT04586543 | Clinical Trial of Selegiline Plus Docetaxel for the Treatment of Metastatic, Castrate-resistant Prostate Adenocarcinoma | unknown | Phase 2 | 110 | László MangelOTHER | 1 | Oct 14, 2020 | clinicaltrials |
| NCT04523896 | HDR Brachytherapy Plus Stereotactic Ablative Prostate Radiotherapy for Patients With Intermediate and High-risk Prostate Cancer(BRAchySABR) | unknown | Phase 2 | 50 | David BüchserOTHER_GOV | 1 | Aug 24, 2020 | clinicaltrials |
| NCT02282137 | 68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer(PSMA) | unknown | Phase 2 | 208 | Ebrahim DelpassandOTHER | 1 | Aug 19, 2020 | clinicaltrials |
| NCT04489745 | Stereotactic Body Radiotherapy (SBRT) for Localized Prostate Cancer | unknown | Phase 2 | 72 | VA Greater Los Angeles Healthcare SystemFED | 0 | Jul 28, 2020 | clinicaltrials |
| NCT04486937 | SC10914 Monotherapy for the mCRPC With g/s BRCA Mutation(mCRPC) | unknown | Phase 1 / Phase 2 | 90 | Jiangxi Qingfeng Pharmaceutical Co. Ltd.INDUSTRY | 0 | Jul 27, 2020 | clinicaltrials |
| NCT03506997 | Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer(PERSEUS1) | unknown | Phase 2 | 100 | Institute of Cancer Research, United KingdomOTHER | 1 | Jul 22, 2020 | clinicaltrials |
| NCT02742675 | Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery) | unknown | Phase 2 | 200 | Fudan UniversityOTHER | 1 | Jul 7, 2020 | clinicaltrials |
| NCT03380806 | Prostate Boost Irradiation With Stereotactic Body RT (SBRT)(PBS) | unknown | Phase 2 | 100 | Juravinski Cancer CenterOTHER | 1 | Jun 4, 2020 | clinicaltrials |
| NCT02691975 | A Safety and Efficacy Study of SHR3680 in Metastatic Castration-Resistant Prostate Cancer Patients | unknown | Phase 1 / Phase 2 | 197 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 13, 2020 | clinicaltrials |
| NCT04188587 | 177Lu-PSMA-I&T PSMA Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer | unknown | Phase 2 | 30 | Nanjing First Hospital, Nanjing Medical UniversityOTHER | 1 | Dec 6, 2019 | clinicaltrials |
| NCT04182594 | Cardiovascular Events in GnRH Agonist vs. Antagonist | unknown | Phase 2 | 80 | Rabin Medical CenterOTHER | 1 | Dec 2, 2019 | clinicaltrials |
| NCT04148885 | A Trial of Paclitaxel (Albumin-binding) for Castration-resistant Prostate Cancer | unknown | Phase 1 / Phase 2 | 44 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Nov 4, 2019 | clinicaltrials |
| NCT03600766 | Mirabegron for Treatment of Erectile Dysfunction in Patients With LUTS Secondry to BPH: A Randomized Study | unknown | Phase 2 | 50 | Mansoura UniversityOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT02759783 | Conventional Care Versus Radioablation (Stereotactic Body Radiotherapy) for Extracranial Oligometastases(CORE) | unknown | Phase 2 / Phase 3 | 245 | Royal Marsden NHS Foundation TrustOTHER | 2 | Aug 21, 2019 | clinicaltrials |
| NCT01682772 | TOPARP: A Phase II Trial of Olaparib in Patients With Advanced Castration Resistant Prostate Cancer(TOPARP) | unknown | Phase 2 | 148 | Institute of Cancer Research, United KingdomOTHER | 1 | Aug 15, 2019 | clinicaltrials |
| NCT03587285 | A Pilot Study of Hormonal Therapy Combined With Central Memory T Cells (Tcm) for Patients With Advanced Prostate Cancer | unknown | Phase 1 / Phase 2 | 11 | Guangzhou University of Traditional Chinese MedicineOTHER | 1 | Aug 1, 2019 | clinicaltrials |
| NCT04031378 | Single Dose Radiotherapy (SDRT) With or Without Adjuvant Systemic Therapy for Oligometastatic Prostate Cancer | unknown | Phase 2 | 100 | Fundacao ChampalimaudOTHER | 1 | Jul 24, 2019 | clinicaltrials |
| NCT03579654 | Study of Proscavax Vaccine in Patients With Localized Prostate Cancer vs Active Surveillance | unknown | Phase 2 | 120 | OncBioMune PharmaceuticalsOTHER | 1 | Mar 6, 2019 | clinicaltrials |
| NCT01685190 | A Study of Prostate and pelvIs Versus prOsTate Alone Treatment for Locally Advanced Prostate Cancer(PIVOTAL) | unknown | Phase 2 | 124 | Institute of Cancer Research, United KingdomOTHER | 1 | Jan 4, 2019 | clinicaltrials |
| NCT02913859 | Hormone Therapy With or Without Definitive Radiotherapy in Metastatic Prostate Cancer | unknown | Phase 2 | 60 | University Hospital Sestre MilosrdniceOTHER | 1 | Oct 11, 2018 | clinicaltrials |
| NCT03696186 | Selective Treatment According to Molecular Subtype of Prostate Cancer(STAMP) | unknown | Phase 2 | 300 | Tianjin Medical University Second HospitalOTHER | 1 | Oct 9, 2018 | clinicaltrials |
| NCT02525068 | A Study of Enzalutamide in Combination With AZD5363 in Patients With mCRPC(RE-AKT) | unknown | Phase 2 | 136 | Institute of Cancer Research, United KingdomOTHER | 1 | Aug 8, 2018 | clinicaltrials |
| NCT03516045 | A Study of 18F-AlF-NOTA-Neurotensin PET/CT for Imaging Prostate Cancer | unknown | Phase 1 / Phase 2 | 65 | Xiangya Hospital of Central South UniversityOTHER | 1 | May 17, 2018 | clinicaltrials |
| NCT03525652 | Therapeutic Vaccine Plus PD-1 Knockout in Prostate Cancer Treatment | unknown | Phase 1 / Phase 2 | 30 | The First Affiliated Hospital of Guangdong Pharmaceutical UniversityOTHER | 1 | May 16, 2018 | clinicaltrials |
| NCT01890096 | A Phase II Trial of High Dose-Rate Brachytherapy as Monotherapy in Low and Intermediate Risk Prostate Cancer | unknown | Phase 2 | 174 | Sunnybrook Health Sciences CentreOTHER | 1 | Apr 17, 2018 | clinicaltrials |
| NCT02313298 | Stereotactic Body Radiotherapy for Organ Confined Prostate Cancer | unknown | Phase 2 | 80 | National Cancer Centre, SingaporeOTHER | 1 | Mar 29, 2018 | clinicaltrials |
| NCT03196388 | Enzalutamide and External Beam Hypofractionated Radiotherapy For Intermediate Risk Localized Prostate Cancer(ENZART) | unknown | Phase 2 | 70 | Fundación Canaria Instituto de Investigación Sanitaria de CanariasOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT03356912 | CABAzitaxel With or Without Prednisone in Patients With Metastatic CAstration REsistant Prostate Cancer Progressed During or After a Previous Docetaxel-based Chemotherapy | unknown | Phase 2 | 220 | Consorzio OncotechOTHER | 1 | Dec 14, 2017 | clinicaltrials |
| NCT03356444 | Docetaxel Versus Abiraterone as First-line Treatment in mCRPC Patients With Intraductal Carcinoma of the Prostate | unknown | Phase 2 | 140 | West China HospitalOTHER | 0 | Nov 29, 2017 | clinicaltrials |
| NCT03344822 | Place of 68Ga-PSMA-11 PET-CT in the Therapeutic Decision at the End of the Initial Staging for High Risk Prostate Cancer Patients(TePSMAG-68) | unknown | Phase 2 / Phase 3 | 33 | Central Hospital, Nancy, FranceOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT02724618 | Nanocurcumin for Prostate Cancer Patients Undergoing Radiotherapy (RT) | unknown | Phase 2 | 64 | Shahid Beheshti University of Medical SciencesOTHER | 1 | Oct 12, 2017 | clinicaltrials |
| NCT02844699 | A Multicenter Randomized Double-blind Placebo-controlled Pilot Study of Safety, Pharmacodynamics and Efficacy of Different Treatments of Immunotherapeutic Drug Mobilan (M-VM3) in Patients With Diagnosed Prostate Cancer | unknown | Phase 1 / Phase 2 | 24 | Panacela Labs LLCINDUSTRY | 1 | Sep 20, 2017 | clinicaltrials |
| NCT02452307 | Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy | unknown | Phase 1 / Phase 2 | 36 | University Hospital TuebingenOTHER | 0 | Aug 17, 2017 | clinicaltrials |
| NCT00851916 | CyberKnife Radiosurgery for Locally Recurrent Prostate CA | unknown | Phase 2 | 20 | CyberKnife Centers of San DiegoOTHER | 1 | Jul 21, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Sep 22, 2021source: clinicaltrials